Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Day of Reckoning for Aging Facilities: Is It Time to Invest in Change?

This article was originally published in The Gold Sheet

Executive Summary

With its acquisition of Hospira, Pfizer joins the ranks of pharmaceutical companies struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades for fear of triggering additional drug shortages. Meanwhile, flexible, modular next-generation facilities that could add capacity where needed are on the horizon.

You may also be interested in...



FDA Shortages Task Force Looks More Broadly To Tackle Root Causes

FDA’s latest drug shortages task force aims to encourage investment in the reliable manufacture of generic sterile injectables that are fundamental to the practice of medicine. While the agency’s first task force continues to work with industry to avert shortages, the second will strike at underlying structural issues that cause persistent shortages of these critical medicines.

Code Cart Crisis: Anatomy Of An Emergency Drug Shortage

How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.

GSK Faces 'Profoundly Difficult' Penicillin Challenge, FDA Warning Letter Says

Aging plant in Worthing, UK, must either dedicate building solely to penicillin or undergo wrenching decontamination before US distribution of non-penicillin products could resume.

Related Content

Topics

UsernamePublicRestriction

Register

PS000950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel